•  
  •  
 

Subject Area

Physical Medicine, Rheumatology and Rehabilitation

Article Type

Original Study

Abstract

Objectives To evaluate the efficacy of combination therapy of sofosbuvir and daclatasvir with or without ribavirin as a treatment of chronic hepatitis C virus (HCV), estimated by the rate of achievement of sustained viral response 12 weeks. Background Direct-acting antiviral agents opened the gate to a new era for the management of HCV. These agents have shown high sustained viral response rates of ~90% in clinical trials, shorter therapies, less toxicity, and interferon-free regimens. Patients and methods This prospective, population-based study included 401 HCV-infected patients, 18–75 years of age, attending the Viral Hepatitis Unit of the National Committee for Control of Viral Hepatitis at Center of Cardiac and Digestive System, Sohag, who were divided into two groups: group I (easy to treat) was treated by sofosbuvir + daclatasvir for 3 months, and group II (difficult to treat) was treated by sofosbuvir + daclatasvir + ribavirin for 3 months. Results There was a high statistically significant difference between the studied groups regarding liver echo pattern, splenic size, fibrosis index based on the 4 factors, blood glucose, international normalized ratio, total bilirubin, serum albumin, aspartate transaminase, and platelet count (P < 0.001). Moreover there was a statistically significant difference regarding diabetes prevalence, alanine transaminase, and hemoglobin (P < 0.05). There was a statistically insignificant difference regarding total leukocytic count and serum creatinine levels (P > 0.05). Conclusion The treatment regimen of sofosbuvir + daclatasvir with/without ribavirin for chronic HCV patients was of high efficacy.

Download

Share

COinS